Protara Therapeutics (TARA) Net Cash Flow (2013 - 2026)

Protara Therapeutics (TARA) has reported Net Cash Flow for 14 consecutive years, with -$34.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 51.05% year-over-year to -$34.9 million; the TTM figure through Mar 2026 stood at -$76.7 million (down 295.57% YoY), while the FY2025 annual figure was -$113.1 million, down 191.83% from the prior year.
• Net Cash Flow declined to -$34.9 million in Q1 2026 per TARA's latest filing, from $37.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $111.0 million in Q4 2024 and bottomed at -$71.3 million in Q1 2025.
• Historically, Net Cash Flow has averaged -$1.2 million across 5 years, with a median of -$210000.0 in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 1808.58% in 2024 and fell as far as 17911.43% in 2024.
• Protara Therapeutics' Net Cash Flow stood at -$23.4 million in 2022, then surged by 124.89% to $5.8 million in 2023, then jumped by 1808.58% to $111.0 million in 2024, then slumped by 66.58% to $37.1 million in 2025, then sank by 194.11% to -$34.9 million in 2026.
• Business Quant data shows TARA's Net Cash Flow at -$34.9 million in Q1 2026, $37.1 million in Q4 2025, and -$18.9 million in Q3 2025.